Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480312 | 0.91 | SMN1; SMN2 (0.54) | SMN1; SMN2HPGDPOLBPKMHSD11B1 | |
| SCHEMBL25075430 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDPOLBPKMHSD11B1 | |
| SCHEMBL26295635 | 0.87 | THRB (0.38) | SMN1; SMN2ALDH1A1KDM4EGAATHRB | |
| SCHEMBL26295676 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2HPGDHSD11B1ALDH1A1MEN1 | |
| SCHEMBL26295673 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2HPGDPOLBPKMHSD11B1 | |
| SCHEMBL101964 | 0.83 | HPGD (0.48) | SMN1; SMN2HPGDPOLBPKMHSD11B1 | |
| SCHEMBL25075216 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2HSD11B1ALDH1A1KDM4EGAA | |
| SCHEMBL25074969 | 0.83 | SMN1; SMN2 (0.52) | SMN1; SMN2HSD11B1ALDH1A1KDM4EGAA | |
| SCHEMBL26494269 | 0.83 | RAB9A (0.40) | HPGDPOLBPKMHSD11B1ALDH1A1 | |
| SCHEMBL26494233 | 0.83 | SMN1; SMN2 (0.46) | SMN1; SMN2HPGDPOLBPKMHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | ENDOTARGET INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230137175-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, BCL9, CRBN | SMN1; SMN2 4438/4885HPGD 4528/4885POLB 2530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.